Illinois makes HIV drug PrEP more available
As the federal government cuts funding for HIV and AIDS research, Illinois is trying to make HIV prevention meds more available.
Why it matters: Better access to the medication could reduce the risk of contraction for those most at risk — men who have sex with men and Black and Hispanic people.
Driving the news: The Illinois Department of Public Health issued an order allowing Illinoisans to obtain the medication PrEP, which can reduce the risk of contracting HIV through sex by 99% when taken correctly, directly from a pharmacist without first requiring a doctor's prescription.
Flashback: Gov. JB Pritzker signed a law in 2022 to allow access to the medication without a prescription, and any pharmacist who wants to offer the medicine must undergo a training program.
"With a large-scale change like this, we needed to ensure that the implementation would be safe, effective, and equitable. That meant engaging local health departments, advocacy groups, pharmacist associations, and sister state agencies to shape a responsible rollout," a spokesperson from IDPH told Axios in a statement.
"We also worked to identify the best ways to monitor program participation and ensure pharmacists were supported with appropriate training and guidance."
The law also specifies that services provided by a pharmacist are covered and reimbursed by insurance at the same rate as when provided by a doctor.
What they're saying: "With threats from the federal government to HIV prevention funding (the HHS draft budget proposed eliminating all — yes, all — HIV prevention funding) it's even more critical to increase the access points where people can get PrEP," AIDS Foundation Chicago (AFC) president John Peller tells Axios in an email.
AFC has helped implement the law across the state, including training for pharmacists and setting reimbursement rates through Medicaid.
By the numbers: Nearly 23,000 people in Illinois were living with HIV and about 19,000 living with AIDS as of December 2024, the most recent available data from IDPH.
There were more than 1,300 new diagnoses of the virus statewide in 2024, down 9% from the previous year.
Black men make up the most new cases since 2017 at more than 3,500, followed by Hispanic men at 2,700.
The 30-39 age bracket is the most common for both men and women in terms of new cases.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences chairman and CEO Daniel O'Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importance of preventive medicine, the fight against HIV, and more.
Forbes
2 hours ago
- Forbes
How AI Is Transforming Breast Cancer Detection and Prevention
From underdiagnosed dense breast tissue to the risk of recurrence, breakthroughs—from DeepLook Medical's imaging AI to the Cleveland Clinic's TNBC vaccine trial—are transforming the fight against breast cancer. Breast cancer remains one of the most prevalent and emotionally fraught diagnoses in medicine. Cases of female breast cancer look set to to rise by 38% worldwide over the next 25 years, while deaths from the disease could increase by 68%, according to an analysis by international scientists. In the U.S. alone, 1 in 8 women will be diagnosed with the disease in her lifetime. Contrary to common perception, only about 10% of breast cancer cases are linked to family history. The remaining 90% are influenced by environmental exposures, lifestyle choices, and other non-hereditary factors, many of which intersect with structural inequalities in healthcare access. DeepLook CEO Marissa Fayer speaking at the The Future of MedTech Conference One of the most persistent challenges in breast cancer detection is dense breast tissue, which can obscure tumors on mammograms and delay diagnosis. Dense breasts don't correlate with body or breast size—they're a function of tissue composition, with more glandular and fibrous tissue and less fat. The CDC estimates that around 50% of women over 40 have dense breasts, but experts believe that number may be much higher. 'The true number is likely closer to 65–70% of all women,' says Marissa Fayer, CEO of DeepLook Medical. 'Most of our global data comes from women with access to mammograms—but millions of women simply aren't screened.' Indeed, dense breast tissue is severely underreported. Millions of women globally—especially in Africa, India, and rural Asia—lack access to regular mammographic screening. Even in developed countries, many go undiagnosed due to gaps in insurance coverage and access to advanced imaging technology. Jewish, Black, and Asian women are disproportionately predisposed to dense breasts, adding complexity to early detection and equity in care. While survival rates have improved over the past two decades, major gaps remain. But a new generation of tools is shifting the breast cancer paradigm—from better detection to early intervention, and from recurrence management to long-term prevention. One of the most promising advances in breast cancer AI detection comes from DeepLook Medical, a Phoenix-based health tech company tackling dense breast detection with DL Precise, an FDA-cleared visual enhancement tool. DeepLook Imaging Unlike traditional computer-aided detection systems that flag anomalies for secondary review, DL Precise enhances the mammogram image itself—supporting radiologists on the first read. It integrates directly into existing 2D and 3D mammography systems and software, requiring no new equipment or imaging protocols. And it's already in use. DL Precise is currently installed at around 300 hospitals, including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, AdventHealth, Geisinger, and Penn Medicine. The clinical impact is measurable: DL Precise has demonstrated a 12% reduction in recall rates, improving diagnostic accuracy while reducing unnecessary callbacks and emotional distress for patients. 'By enhancing clarity and streamlining interpretation, DL Precise empowers radiologists with greater accuracy in recognizing and distinguishing subtle findings while optimizing workflow,' said Dr. Anjali Malik, a breast imaging radiologist at Washington Radiology Associates. 'For patients, this translates to earlier diagnoses, more informed treatment decisions and ultimately, better outcomes. I believe DL Precise represents a pivotal advancement in medical imaging that will redefine the standard of precision in radiology.' DeepLook recently closed the first tranche of its Series A, backed by Xcellerant Ventures and OKG Capital, and is targeting a final close in summer 2025. The company has partnered with Barco, a global leader in medical imaging displays, and Blackford Analysis, owned by Bayer, to enable cloud-native deployment of DL Precise across large systems and OEM platforms. 'AVC is proud to invest in DeepLook Medical, a health tech company revolutionizing how physicians detect and visualize breast cancer in dense breast tissue,' said Aaron Favreau of AZ Venture Capital. 'With their disruptive AI and imaging technology, they are set to dramatically enhance the speed, accuracy and accessibility of medical imaging.' A key differentiator is DeepLook's SaaS-based distribution model. DL Precise is already embedded within hospital imaging systems via channel partners—radiologists simply need to activate it. This model has enabled fast, seamless adoption at scale. As Forbes previously reported, DeepLook is launching a three-phase awareness campaign: In an industry where life-saving technologies often take years to scale, DeepLook Medical is moving faster—and helping radiologists do the same. Detection is improving—but recurrence prevention remains a critical challenge, especially for women with triple-negative breast cancer (TNBC), an aggressive subtype that lacks the hormonal receptors targeted by most therapies. That's why the Cleveland Clinic's TNBC vaccine trial, developed in partnership with Anixa Biosciences, is gaining national attention. Now in Phase 1 trials, the vaccine is being tested in women previously treated for TNBC who are currently cancer-free. It targets α-lactalbumin, a protein present in most TNBC tumors but not in healthy post-lactation breast tissue—training the immune system to recognize and eliminate cancer cells before they return. 'If the vaccine is successful, it has the potential to become a cancer prevention vaccine—similar to the HPV vaccine,' said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. While some headlines suggest the vaccine could lead to broader breast cancer prevention within a decade, researchers urge caution. For now, it's only available to women with prior TNBC, and widespread preventive use is likely 10 to 20 years away, pending trial results and regulatory approvals. Cleveland Clinic researchers are also making progress on the molecular front. A recent study identified a new family of molecules linked to breast cancer growth and recurrence—potential targets for future therapies and immunizations. As Medical Xpress reports, the discovery offers critical insights into how aggressive cancers evolve and reinforces the importance of preventative research. Together, these efforts represent a new frontier in oncology—where recurrence might be preventable, and breast cancer risk could be intercepted before diagnosis ever occurs. Today's breakthroughs in breast cancer care go beyond treatment—they aim to close gaps in detection, recurrence prevention, and equitable access. OpenAI CMO Kate Rouch's X's post about her breast cancer diagnosis. With tools like DL Precise, radiologists are already improving outcomes for women with dense breast tissue—a group historically underserved. And with vaccine trials like Cleveland Clinic's TNBC study, the future of care is shifting toward proactive prevention, not just reactive treatment. The next era of oncology won't be shaped by a single breakthrough. It will be defined by how detection, prevention, and access converge to serve patients more personally—and more powerfully. For some, that convergence is already deeply personal. Kate Rouch, Chief Marketing Officer at OpenAI, recently shared her own breast cancer diagnosis—and how ChatGPT supported her through it. The tool helped explain cancer to her children, manage chemotherapy side effects and even generate personalized meditations. She wrote on X: Stories like Rouch's underscore the growing role of human-centered AI in medicine—not just for clinicians, but for patients navigating complexity, fear and healing. The future of breast cancer AI detection lies not only in identifying tumors more accurately—but in doing so earlier, for more people, with more personalized outcomes. As technologies like DeepLook and AI-powered support tools become embedded in patient journeys, breast cancer care is becoming not just smarter—but more human.
Axios
5 hours ago
- Axios
Accidental death data threatened by Trump CDC cuts
The CDC center that provides a window into how Americans are accidentally killed could see much of its work zeroed out under the Trump administration 2026 budget after it was hit hard by staff cuts this spring. Why it matters: Unintentional injuries are the leading cause of death for Americans younger than 45, and the data the National Center for Injury Prevention and Control churns on fatal car accidents, drug overdose deaths, firearm injuries and even dog bites help inform public health strategies. The Trump budget targets the CDC with more than $3.5 billion in proposed cuts and lists the injury center under "duplicative, DEI or simply unnecessary programs" that can be conducted more effectively by states. Where things stand: The center was hit by layoffs under HHS Secretary Robert F. Kennedy Jr.'s reorganization of federal health agencies, losing about 200 staffers in April who primarily worked on violence prevention and unintentional injuries. That crippled key data repositories, such as a web-based injury statistics system called WISQAR and the National Electronic Injury Surveillance System (NEISS), with few data scientists and other technicians left to crunch the numbers, current employees and advocates say. "Those are existing in name only from here on, because the staff who have the expertise and the know-how and the access to the databases and all of that were RIF'd," Sharon Gilmartin, executive director of the Safe States Alliance, told Axios. Trump's 2026 budget request would eliminate funding for both data repositories and the National Intimate Partner and Sexual Violence Survey (NISVS). Between the lines: Also potentially at risk is the CDC's federal surveillance report of drowning statistics, which found the number of drowning deaths among kids 4 and younger increased 28% during the pandemic, between 2019 and 2022. That information revealed COVID-era patterns, such as kids spending more time at home or distracted parents juggling remote work with child care, that may have increased their risk, Katie Adamson, vice president of health partnerships and policy for YMCA, told Axios. That kind of data, as well as $5 million in funding for drowning prevention programs such as swimming lessons, from groups like the YMCA, has been cut. "Why wouldn't the federal government have a role in [addressing] the leading cause of death in our babies?" Adamson said. The cuts extend beyond the CDC to grantees around the country who use the data to implement prevention strategies, said one CDC official, who spoke on the condition of anonymity because they were not authorized to talk to the press. Among the uses of funding specifically eliminated in the president's budget is money for a network of 11 Injury Control Research Centers at universities around the country that assist in researching the most efficient prevention programs based on the data collected by the CDC. The work includes a University of Michigan study of the effectiveness of anonymous tip lines at schools. Over four years, it identified more than 1,000 opportunities for mental health intervention, with dozens of weapons recovered from schools and several students with school shooting plans. "The return on investment for preventing these kinds of injuries and deaths is enormous," the official said. "If you care about saving dollars, you should be investing in the kind of work that the CDC injury center has historically done. It's not duplicative, it's unique." The other side: HHS has indicated plans for some of the work would be transferred within the planned Administration for a Healthy America. "HHS and CDC remain firmly committed to maintaining the availability of high-quality public health data essential to injury prevention and response nationwide," an HHS spokesman said. "As part of Secretary Kennedy's broader vision to streamline HHS operations and improve government efficiency, the CDC's critical work will continue to inform data-driven strategies that protect the health and safety of the American people." Yes, but: It's not that easy to just shift the work of the injury center and its complex data infrastructure, including laboratory work and response work, to another agency, the CDC official said. "Everybody's really worried around here. We've already lost the world's experts in a lot of these topics and a lot of incredible work in every one of these areas. It's not easy to just turn that back on or rebuild," the CDC official said.
